Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysine 99 of the humanized catalytic antibody 38C2 (h38C2) heavy chain is a highly specialized amino acid residue located at the base of a deep, hydrophobic binding pocket in the variable heavy (VH) domain. This residue is distinguished by an exceptionally low pKa of approximately 6.0, which is significantly lower than the typical pKa of ~10.5 for lysine side chains, making it a potent nucleophile at physiological pH (Wagner et al., 1995; Rader et al., 2003). This unique chemical environment allows the lysine to function as a catalytic center, mimicking the mechanism of Class I aldolases by forming covalent Schiff base intermediates with carbonyl-containing substrates (Sinha et al., 2004). In the field of bioconjugation and drug delivery, this residue serves as the primary site for "chemical programming," where small molecule ligands or prodrugs equipped with 1,3-diketone or beta-lactam functional groups are covalently and site-specifically attached to the antibody (Popkov et al., 2009). This technology, known as Chemically Programmed Antibodies (cpAbs), enables the creation of therapeutic agents that combine the targeting precision of small molecules with the favorable pharmacokinetics and effector functions of a humanized monoclonal antibody.
Covalent conjugation via the formation of a stable enaminedione or Schiff base between the nucleophilic epsilon-amino group of Lys99 and a carbonyl-containing linker (e.g., 1,3-diketone).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysine 99 of humanized catalytic antibody 38C2 heavy chain (h38C2 Lys99).